We’ve developed a new approach to CD47 blockade that is designed to maximize clinical activity and minimize toxicities

Our goal is to transform cancer treatment options for patients by developing ALX148 as a foundational checkpoint immunotherapy

ALX Oncology was founded by a team of industry veterans to address fundamental challenges in blocking CD47 and to realize the full potential of this therapeutic target.

Cancer cells employ CD47, a cell surface protein, as a “don’t eat me” signal to evade detection by the immune system. ALX is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches. We believe our lead product candidate, ALX148, will have a wide therapeutic window to block the “don’t eat me” signal on cancer cells, and to leverage the immune activation of broadly used anti-cancer agents through combination strategies. Based on our clinical results to date in multiple oncology indications showing encouraging anti-tumor activity and tolerability, our strategy is to pursue ALX148 as a potentially critical component for future combination treatments in oncology.

Latest News updated at 19:45:02 UTC

Nov 24, 2020

ALX Oncology Announces December 2020 Virtual Investor Conference Participation

Nov 16, 2020

Zymeworks and ALX Oncology Announce Clinical Collaboration Evaluating Zanidatamab with the CD47 Blocker ALX148 in Patients with Advanced HER2 Expressing Breast Cancer

Nov 12, 2020

ALX Oncology Reports Third Quarter 2020 Financial Results and Provides Clinical Development and Operational Highlights

Twitter

ALX Oncology will be participating in a virtual fireside chat with covering analyst, Michael Yee, at the @JefferiesEvents Virtual London Healthcare Conference today at 1:10 PM ET. View the webcast here: https://bit.ly/3lVzKFC

ALX Oncology is excited to announce our clinical collaboration with @ZymeworksInc to evaluate zanidatamab with our #CD47 blocker #ALX148 in patients with advanced #HER2 expressing breast cancer. https://bit.ly/2UuXzYW $ZYME $ALXO

Load More...

Our Technology

ALX Oncology’s fusion proteins are engineered to bind CD47 with significantly greater affinity than natural SIRPα. Our lead candidate, ALX148, is an intravenously administered fusion protein containing two engineered high affinity CD47 binding domains of SIRPα linked to an inactive Fc region of human immunoglobulin.

LEARN MORE